ESTRO 2021 Abstract Book

S632

ESTRO 2021

Neurology Maastricht University Medical Center +, Maastricht, The Netherlands; 6 Maastro Clinic, Department of Radiation Oncology (Maastro), Maastricht, The Netherlands

Purpose or Objective Patients treated with cranial radiation therapy (RT) can develop neurocognitive deficits, which are reflected in for example impaired memory, attention, processing speed and reduced quality of life. The extent of these delayed adverse effects potentially varies with radiation dose, hippocampal dose, -brain volume irradiated, and age at treatment. In order to assess short - and long-term neurocognitive decline in patients treated with RT, we implemented standardized neurocognitive testing as a daily clinical routine in our radiotherapy institute for patient cohorts receiving radiotherapy to the brain. Materials and Methods Since April 2019, patients treated for a neurological tumor, head and neck cancer (HN) with radiation dose in the brain or patients treated for prophylactic cranial irradiation (PCI) receive a neurocognitive test before RT (baseline), 6 months & yearly after RT. All radiation oncology nurses were trained in collaboration with the department of clinical Phychology at MUMC+, to conduct a neurocognitive test and their skills are yearly certified and implemented in our Learning Management System The neurocognitive test selected for implementation include the Hopkins Verbal learning test (HVLT), Trail Making Test (TMT) A&B, and the Controlled Oral Word Association (COWA).

All information is stored in our Electronic Patient Record, from which we developed a Business Intelligence (BI) dashboard to provide feedback on data collection and facilitates further data analysis. Results At the start of clinical testing (April 2019) 73% of the radiation oncology nurses were certified to conduct neurocognitive testing. This number has grown to 100%. Between April 2019 and April 2021, 725 (92% compliance) neurocognitive test were conducted, 423 neurocognitive tests at baseline (95.7% compliance), 180 tests at 6 months (84.5% compliance) and 84 tests at 1 year (Compliance 90.3%) after RT. We observed 4 umbrella reasons for non-compliance: 1. Patient did not attend appointment (N=31; 5%),2. Patient is unable to perform the test due to illness (N=12; 1.6%),3. Patient does not want to perform the test (N=10; 1.4%),4. Various causes, (N=21; 2.9%) These include: difficulty speaking, hearing problems, previous irradiation and fear of Covid-19.

The BI report provides insight into the number of tests performed. It enables selection of sub-populations of patients for further analysis and allows to evaluate performance over time on an individual level. In addition, the causes of non-compliance or incomplete results can be monitored, which allows corrections to process and/or data collection early on. Conclusion We successfully implemented neurophysiological testing in a radiotherapy setting in order to detect cognitive impairment as a possible late side effect of cranial irradiation. The implementation of neurocognitive testing in our clinic enables future research on dose-effect relationship between areas of the brain and cognitive decline. PD-0798 Development and results of a patient-reported treatment experience questionnaire on a 1.5 T MR-Linac H. Barnes 1 , S. Alexander 1 , L. Bower 2,3 , J. Ehlers 4 , C. Gani 4 , T. Herbert 1 , R. Lawes 5 , P. Krause Møller 6 , T. Morgan 2,3 , M. Nowee 7 , G. Smith 1 , B. van Triest 7 , N. Tyagi 8 , L. Whiteside 9 , H. McNair 1,3 1 Royal Marsden NHS Foundation Trust, Department of Radiotherapy, Sutton, United Kingdom; 2 Royal Marsden NHS Foundation Trust, Bob Champion Unit, Sutton, United Kingdom; 3 Institute of Cancer Research, Division of Radiotherapy and Imaging, Sutton, United Kingdom; 4 University Hospital Tübingen, Department for Radiation Oncology, Tübingen, Germany; 5 Royal Marsden NHS Foundation Trust1, Department of Radiotherapy, Sutton, United Kingdom; 6 Odense University Hospital, Department of Oncology, Odense, Denmark; 7 Netherlands Cancer Institute, Department of Radiotherapy, Amsterdam, The Netherlands; 8 Memorial Sloan Kettering Cancer Centre, Department of Medical Physics, New York, USA; 9 The Christie NHS Foundation Trust, Department of Radiotherapy, Manchester, United Kingdom

Purpose or Objective With the implementation of new radiotherapy technology, it is imperative that patient experience is